Oralair

Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate, the active ingredient in Oralair, is a allergen immunotherapy presented as a sublingual tablet for sublingual use. It is indicated for the treatment of grass‑pollen‑induced allergic rhinitis and related seasonal symptoms in adolescents and adults.

GNH USA supplies Oralair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory‑approved batches for global distribution.

Oralair is used in allergen immunotherapy to modify the immune response to grass pollen exposure. - Grass pollen allergic rhinitis: reduces nasal congestion, sneezing and itching during the grass season. - Seasonal allergic rhinoconjunctivitis due to grass pollen: improves ocular symptoms and overall quality of life. - Grass pollen‑induced asthma (adjunct): may lessen reliance on rescue medication in sensitised patients.

Common and serious adverse reactions have been reported with sublingual grass pollen immunotherapy. Common Side Effects: - Oral itching or mild irritation. - Swelling of the lips or tongue. - Mild throat discomfort. - Transient gastrointestinal upset. - Localized rash at the site of administration. Serious or Rare Side Effects: - Anaphylaxis or severe systemic allergic reaction. - Angioedema involving the face or airway. - Severe bronchospasm requiring emergency treatment. - Persistent eosinophilic esophagitis. - Cardiovascular collapse (very rare).

Before prescribing Oralair, clinicians should consider the following precautions. - Contraindication: active systemic allergic reaction to the tablet or any component. - Caution: use in patients with uncontrolled asthma; ensure asthma is stable before initiation. - Monitoring: observe patients for at least 30 minutes after the first dose for signs of systemic reaction. - Pregnancy: safety not established; weigh potential benefits against unknown risks. - Breastfeeding: limited data; consider risk‑benefit assessment. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Oralair may interact with other medications or substances that affect immune response or increase the risk of allergic reactions. Major Interactions (Avoid): - Beta‑blockers: may blunt response to anaphylaxis treatment. - ACE inhibitors: can exacerbate angioedema risk. - Immunosuppressants: may reduce efficacy of immunotherapy. Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of systemic reaction. - NSAIDs: can increase gastrointestinal irritation. - Alcohol: may enhance oral mucosal irritation.